This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Johnson & Johnson said Monday that it would purchase Ambrx Biopharma for nearly $2 billion, picking up a company specializing in targeted chemotherapy treatments — one of the hottest areas of cancer drugdevelopment. The deal, disclosed as the biopharma field marked the first day of the annual J.P.
MADRID — Merck is paying billions of dollars to partner with Daiichi Sankyo on a series of cancer drugs, underscoring the excitement around targeted chemotherapy treatments. billion more is on the table depending on the success of the drugs in development. billion over the next two years.
The chemotherapy Christine Ko was prescribed for her breast cancer is pretty much a guarantee for losing your hair. The company is currently developing an antibody that might reliably protect the head’s hair follicles from chemotherapy damage — if it works. But, to her, it wasn’t much of an option.
For three decades, adults have benefited from a revolution in oncology treatment, as immunotherapies and targeted drugs have joined or replaced older, blunter tools like chemotherapy and radiation. Children have been less fortunate.
It responds poorly to chemotherapy and is usually driven by a mutation that can’t be drugged with traditional approaches. Chimerix’s drug, known as dordaviprone, isn’t a cure. It often wraps itself around a patient’s brain stem, preventing surgeons from safely excising it.
The Phase 3 trial tested the PD-1 targeting antibody retifanlimab in combination with chemotherapy versus chemotherapy alone in patients with recurrent or metastatic squamous cell carcinoma of the anal canal. Retifanlimab was developed by Incyte and is approved as Zynyz in Merkel cell carcinoma.
MADRID — A Roche drug lowered the risk of recurrence or death by 76% versus chemotherapy for patients with a type of early non-small cell lung cancer, according to data from a Phase 3 trial presented Saturday. The standard treatment after surgery for these patients is chemotherapy.
But she avoided digging into one particular subject: what she might have to endure with chemotherapy and radiation. When Rachel Guberman found out she had brain cancer, she did so much reading and Googling about the disease that she joked she had reached the end of the internet. Continue to STAT+ to read the full story…
While the results assuaged some of the safety fears that flared when initial information was released over the summer, they only heightened concerns about the drug’s ability to outperform standard chemotherapy — though they perhaps pointed to an opportunity for the drug in a subset of patients.
Pharmacists increasingly are being asked to make drugs in bulk for hospitals that are in short supply, and they’re even beginning to make chemotherapies. Hospitals’ reliance on pharmacist-made drugs, a practice called compounding, has risen in step with worsening drug shortages.
MADRID — Results presented Monday could expand the use of a Novartis therapy for metastatic prostate cancer, moving it from a treatment used after chemotherapy to one with demonstrated benefits beforehand as well.
LONDON — AstraZeneca said on Monday that a new lung cancer treatment outperformed standard-of-care chemotherapy in a trial, but investors found the results less impressive than anticipated, sending company shares down in early trading.
As drugdevelopment professionals know, global health crises like the COVID-19 pandemic provide the public with valuable insights into how clinical research and regulatory processes work.
The PSMAfore results are the second positive set of data for Pluvicto in a Phase III trial, after the VISION clinical trial, where PSMA–positive mCRPC patients who received Pluvicto plus standard of care (SoC) after ARPI and taxane-based chemotherapy, showed statistically significant reduction in risk of death. The PSMAfore study.
Still, when doctors told her last year that the cancer was growing despite two operations, radiation therapy, and a fifth regimen of chemotherapy, the retired business-meeting facilitator decided to do something unorthodox: spend $83,000 out of pocket on an unproven experimental cancer vaccine. Her husband said he had no regrets.
The US Food and Drug Administration (FDA) has awarded Orphan Drug Designation (ODD) to Avacta Group’s lead pre|CISION drug candidate, AVA6000, to treat soft tissue sarcoma. Updated using the pre|CISION technology, AVA6000 is a kind of generic chemotherapy doxorubicin.
Antibody-drug conjugates (ADCs), such as datopotamab deruxtecan (Dato-DXd) and trastuzumab deruxtecan, have demonstrated compelling evidence of efficacy in oncology across numerous diseases in recent months.
The drug was evaluated in four Phase II/III clinical trials in patients previously given chemotherapy and/or failed radiation therapy. FTD facilitates drugdevelopment and can expedite the review of drugs for serious conditions to help address unmet medical needs.
” Hopes were high that a drugdeveloped by Sangamo based on its zinc finger nuclease (ZFN) genome-editing technology could lead to the first therapy that could correct the genetic defect n MPS I, but that candidate – called SB-318 – flunked out in a clinical trial reported in 2019 and was discontinued.
On Wednesday (28 April), the focus will shift to Keytruda and Tecentriq as first-line treatments for UC patients unable to be treated with cisplatin-containing chemotherapy – which got the go-ahead in 2017 and 2018, respectively.
AZ estimates that approximately 70% of breast cancer tumours are considered HR-positive and HER2-low or negative and, if first-line endocrine therapies fail, their only option currently is single-agent chemotherapy.
All these factors will support the growth of in-house R&D-driven pharmaceutical companies and bring more innovative drugs to Asian markets.”. Chemotherapy still accounted for 72.6% Mei says that oncology is one of the key region-specific unmet medical needs Antengene is hoping to address with innovative drugs.
The discovery of MEN1 mutation as a resistance mechanism indicates that new drugs that targeting menin or other chromatin-associated proteins could prevent or delay revumenib resistance or treat patients who have become resistant to the drug.
In trials, Trodelvy significantly improved both progression free survival (PFS) and overall survival (OS) in adults with locally advanced or metastatic TNBC without brain metastases – who had received at least two prior chemotherapy regimens including a taxane – compared with a range of single-agent chemotherapies.
The EAMS provides a route for clinicians and patients in desperate need of treatment options to try experimental therapies before formal approval, with the drugdeveloper generally providing the drug at no cost. Novartis reckons in time the drug could become a $2 billion-a-year blockbuster.
After surgery, strategic combinations of radiotherapy, chemotherapy like temozolomide, and other forms of treatment, such as immunotherapy or the use of an electric field cap, are employed. For example, radiotherapy and chemotherapy together entails up to six month? Two weeks later, patients began standard radiation and chemotherapy.
Understanding the mechanism of PPIs and developing methods to target aberrant ones has been a key strategy in drugdevelopment. From the cluster, the protein TMEM17 was identified as a novel CSC-related gene, whose depletion can “suppress the proliferation of colorectal cancer (CRC) cells and sensitise CRC cells to chemotherapy.
As of 2018, there were over 1,100 cancer therapies in development, and as of 2020, 362 of them were cell and gene therapies. As a result, there is a need for continued innovation and increased efficiency in terms of drugdevelopment to manage cost, complexity and speed to provide potentially transformative therapies for cancer patients.
As a result, when the patient’s lymphoma relapses after treatment with chemotherapy, BV and CPIs, there are no effective treatment alternatives for these patients. Finally, Andreas looks at the prospects for antibodies that target the innate immune system in treating both haematological malignancies and solid tumours.
The green light for Pemazyre (pemigatinib) has been hailed by cholangiocarcinoma charity AMMF, which said it was a “major milestone” in the fight against the “Cinderella” cancer, which for years has been overlooked by drugdevelopers.
Roche’s drug is already FDA-approved as a monotherapy and in combination with Avastin (bevacizumab) and chemotherapy for previously-untreated NSCLC with high PD-L1 expression. Meanwhile, drugs targeting TIM-3, LAG3, VISTA and STING also coming through development.
In order to reduce the global healthcare impact of the evolving AMR situation, companies such as Micreos Pharmaceuticals are taking a novel and highly innovative approach to antibacterial drugdevelopment by developing targeted antimicrobial products. Antimicrobial Agents and Chemotherapy 2022. References. Herpers, P.
If left unchecked, it may soon not be possible to use antibiotics as prophylaxis for immunocompromised patients during chemotherapy or organ transplants. Moreover, without effective antibiotics, epidemic bacterial infections will become common in the developed world and the risk of infections after surgery will increase.
The filing includes the UNITY-CLL phase 3 trial, a randomised study comparing the U2 combination therapy with an active control arm in which patients received Roche’s Gazyvaro plus chlorambucil chemotherapy in both treatment-naïve patients and those with relapsed/refractory disease.
For example, numerous publications have highlighted the role of the gut microbiome in improving the efficacy and diminishing the toxicity of chemotherapeutic drugs. Emerging Evidence Of The Gut Microbiome In Chemotherapy: A Clinical Review. eClinicalMedicine. 2023; 62:102111. Oh B, Boyle F, Pavlakis N, et al.
A gene-editing drugdeveloped by CRISPR Therapeutics and Vertex Pharma has continued to show impressive results in clinical trial, with an update at the EHA congress showing long-term effects on the symptoms of both beta thalassaemia and sickle cell disease.
Almost all of the patients had been previously treated with chemotherapy and immunotherapy. KRAS mutations are seen in around a quarter of NSCLC tumours, with KRAS G12C mutations in particular found in around 13% of cases, but the target defied drugdevelopers for decades.
After a string of disappointments including the failure of bintrafusp alfa , a drugdeveloped with Germany’s Merck KGaA in lung cancer, any approval is welcome news.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drugdevelopment data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drugdevelopment data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drugdevelopment data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drugdevelopment data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
By reaching cancer cells that have already spread throughout the body, a targeted radiopharmaceutical treatment offers an alternative for patients with advanced cancer when standard lines of treatment, such as chemotherapy, have failed. To address these challenges, radiopharmaceutical companies have developed a variety of approaches.
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content